Establishment of Joint Steering Committee. The Parties hereby establish a Research Program steering committee (the “Joint Steering Committee” or “JSC”) that will be responsible for overall supervision and direction of, and for making decisions related to, the Parties’ activities under the Workplans.
Establishment of Joint Steering Committee. The parties hereby establish a Joint Steering Committee (the "JSC") comprised of six (6) members, with three (3) representatives appointed by each party, one of whom from each party shall fulfill the role of alliance manager for the collaboration. The members initially designated by SB are John Xxxxxxx, Xxry Xxxxxxxx, xxd Mitcxxxx Xxxxx. Xxe members initially designated by ArQule are Norton Peet, Davix Xxxxxxxxx, xxd Sheixx XxXxxx. Xxe JSC shall be chaired by one of the SB representatives. A party may change any of its representatives to the JSC at any time upon written notice to the other party.
Establishment of Joint Steering Committee. In order to fulfil the objectives of the Research Project(s), the parties agree to establish a Joint Steering Committee (“JSC”) and a Joint Operating Team (“JOT”) with the aim to, prepare and adopt strategies for the implementation of the Research Program, subject to the provisions of this Agreement. “* Portions of this document marked with **** have been omitted pursuant to a request for confidential treatment submitted with the SEC.”
Establishment of Joint Steering Committee. The Parties will establish a joint steering committee (the “JSC”) within thirty (30) days of the Effective Date, to oversee the performance of the Development Plan. Each Party will appoint three (3) employees with senior level authority and expertise to serve as their representatives on the JSC. From time to time, on written notice to the other Party, Micromet and Amgen each may substitute any of its representatives on the JSC. Each Party will designate one of its members of the JSC as the “Co-Chair.” Subject to the provisions of this Section 2, the JSC will establish its own procedural rules for its operation.
Establishment of Joint Steering Committee. The Parties will establish a joint steering committee (the “JSC”) within thirty (30) days of the Effective Date, to oversee the research, development and Commercialization of the Product(s) and the activities to be performed by the JPTs under this Agreement. The JSC will be in place until (i) the expiration of the [***] , or (ii) the [***] of the [***] in the first [***] , whichever is longer. The Parties anticipate that the JSC will manage the collaboration in a cooperative and transparent manner, in accordance with the principles and procedures described in this Agreement. Each Party will appoint three (3) employees with senior level and decision making authority and expertise to serve as their representatives on the JSC. From time to time, on written notice to the other Party, Micromet and BI each may substitute any of its representatives on the JSC. Each Party will designate one of its members of the JSC as the “Co-Chair.” Subject to the provisions of this Section 2, the JSC will establish its own procedural rules for its operation. *** Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended. ***Text Omitted and Filed Separately Confidential Treatment Requested Under 17 C.F.R. §§ 200.80(b)(4), and 240.24b-2
Establishment of Joint Steering Committee. Upon the Effective Date, the Parties will establish a joint steering committee (“Joint Steering Committee” or “JSC”) to provide oversight for the research, development and commercialization undertaken pursuant to this Agreement for Collaboration Products during the Term. The Joint Steering Committee will be composed of [***] representatives from each Party. The representatives of each Party to the JSC as of the Effective Date are listed on Schedule H. Either Party may change its representatives to the JSC upon prior written notice to the other Party in accordance with this Agreement. It is anticipated that the membership of the JSC may change over time in accordance with the development stage of the Collaboration Product(s). Each Party shall insure that the representatives named by such Party [***] Certain information on this page has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. for membership on the JSC have the requisite seniority level and expertise to oversee the activities of the collaboration during the Term. Any member of the Joint Steering Committee may designate a substitute of at least equal seniority and a similar level of expertise to attend and perform the functions of that member at any meeting of the Joint Steering Committee.
Establishment of Joint Steering Committee. Promptly after the License Effective Date, the Parties will establish a joint steering committee (the “JSC”) to oversee the [***]. Each Party will appoint three employees to serve as their representatives on the JSC. From time to time, on written notice to the other Party, Micromet and Bayer each may substitute any of its representatives on the JSC unable to attend a meeting or replace a representative by a new one. Each Party will designate one of its members of the JSC as the “Co-Chair.” Subject to the provisions of this Section 3, the JSC will establish its own procedural rules for its operation. *** Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended.
Establishment of Joint Steering Committee. The Parties will establish a joint steering committee (the “JSC”) within thirty (30) days of the Effective Date, to oversee the development of the Products and the activities to be performed by the JPT under this Agreement. Each Party will appoint three (3) employees with senior level authority and expertise to serve as their representatives on the JSC. From time to time, on written notice to the other Party, Micromet and Sanofi each may substitute any of its representatives on the JSC. Each Party will designate one of its members of the JSC as a co-chairperson (each a “Co-Chair”). Subject to the provisions of this Section 2, the JSC will establish its own procedural rules for its operation. *** Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended. ***Text Omitted and Filed Separately Confidential Treatment Requested Under 17 C.F.R. §§ 200.80(b)(4), and 240.24b-2
Establishment of Joint Steering Committee. The parties shall establish a Joint Steering Committee (“JSC”), which shall have a total of four members, with two members appointed by each party. Members of the JSC may be represented at any meeting by a designee appointed by such party for such meeting, provided that reasonable advance notice is provided to the other party and such designee, if not an employee of the party, shall be subject to an appropriate confidentiality agreement. Each party shall be free to change its members on prior written notice to the other party. Each party may, in its discretion and upon reasonable notice to the other party, invite non-JSC employees and consultants of such party to attend such meeting, provided that such non-JSC employees and consultants shall be subject to appropriate confidentiality agreements. The JSC shall exist until the expiration or termination of its responsibilities set forth in this Agreement.
Establishment of Joint Steering Committee. The Parties hereby establish a Joint Steering Committee, or JSC, to oversee and manage the product development and commercialization collaboration contemplated by this Agreement. The JSC will be composed of up to three (3) representatives of each Party, who shall be appointed (and may be replaced at any time) by such Party on written notice to the other Party in accordance with this Agreement. Such representatives shall include individuals within the senior management of each Party with expertise in drug development and commercialization. The initial JSC members from each Party are listed on Exhibit A attached hereto. Any member of the JSC may designate a substitute to attend and perform the functions of that member at any meeting of the JSC. The JSC will meet at least twice each year during the Term of this Agreement, or at any frequency agreed by the JSC, to conduct the activities described in Section 3.1(b) below. The representatives from each Party will collectively have one vote in decisions, with decisions for overall product development strategy made by unanimous vote.
